Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

The restaurant group announced Tuesday that Jose Alberto Dueñas is stepping down. Chief financial officer Paul Carbone, a ...

(Reuters) -Oilfield services provider Flowco Holdings on Tuesday said it is seeking a valuation of up to $2 billion in its ...

Spanish travel technology firm HBX Group is considering announcing plans for an initial public offering as early as next week ...

Quadrant Future Tek IPO experienced a strong opening with full subscription within hours, driven by high demand in the retail ...

Positive market feedback has generated significant interest, with shares trading at a ₹97 premium in the grey market.

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...

Once the allotment of Fabtech Technologies IPO shares is finalised, investors who applied for the offering can check the ...

Smithfield Foods on Monday made public its paperwork for its New York initial public offering as the maker of Farmland bacon ...

Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of 2025.

While institutional demand from qualified buyers has been tepid, the grey market is buzzing with a premium of around 69%, hinting at strong listing gains when the shares make their debut on January 14 ...

The main difference between going public through an initial public offering (IPO) and staying private lies in ownership ...